C. Alemany, M. Patel, Zahi I. Mitri, J. Sparano, V. Borges, D. Makower, P. Klein, J. Lawrence, Trinh L. Le, J. Zujewski, Erika Harmilton
{"title":"摘要:OP-1250在晚期和/或转移激素受体阳性(HR+), HER2阴性(HER2−)乳腺癌成人患者中的1/2期剂量递增和扩展研究","authors":"C. Alemany, M. Patel, Zahi I. Mitri, J. Sparano, V. Borges, D. Makower, P. Klein, J. Lawrence, Trinh L. Le, J. Zujewski, Erika Harmilton","doi":"10.1158/1535-7163.targ-21-p037","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":20348,"journal":{"name":"Poster Presentations - Proffered Abstracts","volume":"43 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Abstract P037: A phase 1/2 dose escalation and expansion study of OP-1250 in adults with advanced and/or metastatic hormone receptor-positive (HR+), HER2-negative (HER2−) breast cancer\",\"authors\":\"C. Alemany, M. Patel, Zahi I. Mitri, J. Sparano, V. Borges, D. Makower, P. Klein, J. Lawrence, Trinh L. Le, J. Zujewski, Erika Harmilton\",\"doi\":\"10.1158/1535-7163.targ-21-p037\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":20348,\"journal\":{\"name\":\"Poster Presentations - Proffered Abstracts\",\"volume\":\"43 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Poster Presentations - Proffered Abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1535-7163.targ-21-p037\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Poster Presentations - Proffered Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1535-7163.targ-21-p037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Abstract P037: A phase 1/2 dose escalation and expansion study of OP-1250 in adults with advanced and/or metastatic hormone receptor-positive (HR+), HER2-negative (HER2−) breast cancer